Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 4, 2008, Pages 859-868

  Meers, P ^a   Neville, M ^a   Malinin, V ^a   Scotto, A W ^a   Sardaryan, G ^a   Kurumunda, R ^a   Mackinson, C ^a   James, G ^b   Fisher, S ^b   Perkins, W R ^a  

^a Transave Inc   (United States)

^b MONTANA STATE UNIVERSITY   (United States)

Author keywords

Cystic fibrosis; Drug delivery; Inhaled liposomes

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ARIKACE; FLUORESCENT DYE; LIPOSOME; RHAMNOLIPID; TOBRAMYCIN; UNCLASSIFIED DRUG;

AGAR MEDIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BIOFILM; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG TISSUE LEVEL; EPIFLUORESCENCE MICROSCOPY; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GRAM NEGATIVE INFECTION; IN VIVO STUDY; LUNG INFECTION; NEBULIZATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; RAT; SINGLE DRUG DOSE; SPUTUM; SUSTAINED DRUG RELEASE;

ADMINISTRATION, INHALATION; AMIKACIN; ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; COLONY COUNT, MICROBIAL; FEMALE; LIPOSOMES; LUNG; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RATS; RATS, SPRAGUE-DAWLEY; SPUTUM;

EID: 41149105955     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn059     Document Type: Article

References (40)

1. Chmiel JF, Davis PB. State of the art: Why do the lungs patients with cystic fibrosis become infected and why can't they clean the infection? Respir Res 2003; 4: 8.
2. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-51.
3. Pilewski JM, Frizzell RA. Role of CFTR in airway disease. Physiol Rev 1999; 79: S215-55.
4. Singh PK, Schaefer AL, Parsek MR et al. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000; 407: 762-4.
5. Parsek MR, Greenberg EP. Acyl-homoserine lactone quorum sensing in Gram-negative bacteria: A signaling mechanism involved in associations with higher organisms. Proc Natl Acad Sci USA 2000; 97: 8789-93.
6. Worlitzsch D, Tarran R, Ulrich M et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109: 317-25.
7. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science 1999; 284: 1318-22.
8. Saora W, Kim EJ, Zeng AP. Physiological responses of Pseudomonas aeruginosa PAO1 to oxidative stress in controlled microaerobic and aerobic cultures. Microbiology 2002; 148: 3195-202.
9. Chambless JD, Hunt SM, Stewart PS. A three-dimensional computer model of four hypothetical mechanisms protecting biofilms from antimicrobials. Appl Environ Microbiol 2006; 72: 2005-13.
10. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002; 416: 740-3.
11. Hoffman LR, D'Argenio DA, MacCoss MJ et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005; 436: 1171-5.
12. Le Brun PPH. Pharmacokinetic modeling of tobramycin after high dose inhalation in patients with cystic fibrosis. In: Optimization of Antibiotic Inhalation Therapy in Cystic Fibrosis. Chapter 7, PhD Thesis. Rijksuniversiteit Groningen, 2001.
13. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004; 1: 338-44.
14. Beaulac C, Sachetelli S, Lagace J. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa. J Drug Target 1999; 7: 33-41.
15. Beaulac C, Clement-Major S, Hawari J et al. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob Agents Chemother 1996; 40: 665-9.
16. Marier JF, Brazier JL, Lavigne J et al. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: A pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J Antimicrob Chemother 2003; 52: 247-52.
17. Sanders NN, Van Rompaey E, De Smedt SC et al. On the transport of lipoplexes through cystic fibrosis sputum. Pharm Res 2002; 19 451-6.
18. O'Toole GA, Kolter R. Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: A genetic analysis. Mol Microbiol 1998; 28: 449-61.
19. Wolff RK, Dorato MA. Toxicologic testing of inhaled pharmaceutical aerosols. Crit Rev Toxicol 1993; 23: 343-69.
20. Cantin AM, Woods DE. Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Am J Respir Crit Care Med 1999; 160: 1130-5.
21. Cash HA, Woods DE, McCullough B et al. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am Rev Respir Dis 1979; 119: 453-9.
22. Sanders NN, De Smedt SC, Van Rompaey E et al. Cystic fibrosis sputum: A barrier to the transport of nanospheres. Am J Respir Crit Care Med 2000; 162: 1905-11.
23. Salem II, Flasher DL, Düzgüneş N. Liposome encapsulated antibiotics. Methods Enzymol 2005; 391: 261-91.
24. Conley J, Yang H, Wilson T et al. Aerosol delivery of liposome-encapsulated ciprofloxacin: Aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob Agents Chemother 1997; 41: 1288-92.
25. Knight V, Koshkina NV, Waldrep JC et al. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 1999; 44: 177-86.
26. Ahmed K, Gribbon PN, Jones MN. The application of confocal microscopy to the study of liposome adsorption onto bacterial biofilms. J Liposome Res 2002; 12: 285-300.
27. Kim HJ, Jones MN. The delivery of benzyl penicillin to Staphylococcus aureus biofilms by use of liposomes. J Liposome Res 2004; 14 123-39.
28. Mugabe C, Halwani M, Azghani AO et al. Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50 2016-22.
29. Ochsner UA, Snyder A, Vasil AI et al. Effects of the twin-arginine translocase on secretion of virulence factors, stress response, and pathogenesis. Proc Natl Acad Sci USA 2002; 99: 8312-7.
30. Lema b, Dryja D, Vargas I et al. Pseudomonas aeruginosa from patients with cystic fibrosis affects function of pulmonary surfactant. Pediatr Res 2006, 47: 121-6.
31. Lanotte P, Mereghetti L, Lejeune B et al. Pseudomonas aeruginosa and cystic fibrosis: Correlation between exoenzyme production and patient's clinical state. Rediatr Pulmonol 2003; 36: 405-12.
32. Davey ME, Caiazza NC, O'Toole GA. Rhamnolipid surfactant production affects biofilm architecture in Pseudomonas aeruginosa PAO1. J Bacteriol 2003; 185: 1027-36.
33. Döring G, Worlitzsch D. Inflammation in cystic fibrosis and its management. Paediatr Respir Rev 2000; 1: 101-6.
34. Lequette Y, Greenberg EP. Timing and localization of rhamnolipid synthesis gene expression in Pseudomonas aeruginosa biofilms. J Bacteriol 2005; 187: 37-44.
35. Read RC, Roberts P, Munro N et al. Effect of Pseudomonas aeruginosa rhamnolipids on mucociliary transport and ciliary beating. J Appl Physiol 1992; 72: 2271-7.
36. Walters MC, 3rd, Roe F, Bugnicourt A et al. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003; 47: 317-23.
37. Miller MH, Feinstein SA, Chow RT. Early effects of β-lactams on aminoglycoside uptake, bactericidal rates, and turbidimetrically measured growth inhibition in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1987; 31: 108-10.
38. Brooun A, Liu S, Lewis K. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2000; 44: 640-6.
39. Spoering AL, Lewis K. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J Bacteriol 2001; 183: 6746-51.
40. Cogan N, Cortez R, Fauci L. Modelling physiological resistance in bacterial biofilms. Bull Math Biol 2005; 67: 831-3.